| Hengqu (hetrombopag) / Jiangsu Hengrui Pharma |
ChiCTR-OOC-15006824: Non-intervention clinical trial on prevention of recurrence and metastasis of postoperative colorectal cancer with tonifying qi-blood method |
|
|
| Recruiting | N/A | 216 | | Fuzheng Chinese medicine ;Quxie Chinese medicine ;Fuzhengquxie Chinese medicine ;western medicine | Shanghai municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine; Shanghai municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, the scientific research foundation of Shanghai Health Bureau (20134117) | colorectal cancer | | | | |
ChiCTR-POC-16009499: Therapy with FZQXF to prevent the relapse of postoperative patients with early lung adenocarcinoma patients: a multicenter, large sample, cohort study, controlled clincal trial |
|
|
| Not yet recruiting | N/A | 480 | | NCCN ;fuzhengquxiefang | Department of Oncology of Shanghai Traditional Chinese Medicine Hospital; Shanghai Traditional Chinese Medicine Hospital, Clinical Research Plan of SHDC | Early lung adenocarcinoma | | | | |
ChiCTR-OOB-15006900: A clinical study about The Traditional Chinese medicine prescription-Fuzhengquxie on the effect of immune function and survival period in patients with early stage non small cell lung cancer |
|
|
| Not yet recruiting | N/A | 300 | | Fuzhengquxie prescription | Department of Oncology of Shanghai Traditional Chinese Medicine Hospital; Shanghai Traditional Chinese Medicine Hospital, self-provide fund | Non small cell lung cancer | | | | |
NCT05160857: Clinical Study on the Efficacy and Safety of Hetropapa Ethanolamine Tablets in the Treatment of Thrombocytopenia Caused by Concurrent Radiotherapy and Chemotherapy in Cervical Cancer |
|
|
| Not yet recruiting | N/A | 30 | RoW | Herombopag Olamine | Second Hospital of Shanxi Medical University | Tumor Chemotherapy-related Thrombocytopenia | 12/22 | 12/23 | | |
NCT06376435: A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in Concurrent/Sequential Radioimmunoinduced Thrombocytopenia |
|
|
| Not yet recruiting | N/A | 500 | NA | Herombopag Olamine Tablets | Hebei Medical University Fourth Hospital | Cancer, Therapy-Related | 07/26 | 07/26 | | |
NCT05727917: Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation |
|
|
| Recruiting | N/A | 78 | RoW | Hetrombopag, placebo | Institute of Hematology & Blood Diseases Hospital | Hematological Disease, Allogeneic Hematopoietic Stem Cell Transplantation | 05/24 | 10/24 | | |
ChiCTR2200058727: A prospective and exploratory clinical study of Herombopag Olamine tablets in patients with malignant digestive tract tumors associated with tumor therapy-associated thrombocytopenia |
|
|
| Not yet recruiting | N/A | 30 | | Herombopag Olamine tablets | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Jiangsu HengRui Medicine Co., Ltd. | CTRT | | | | |
ChiCTR2300077314: Efficacy and Safety of Hetrombopag in Treatment of Radiotherapy-Induced Thrombocytopenia |
|
|
| Not yet recruiting | N/A | 53 | | Hetrombopag | Shandong Cancer Hospital & Institute; Shandong Cancer Hospital & Institute, Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Thrombocytopenia | | | | |
ChiCTR2000036042: Therapy with FZQXF to prevent the relapse of postoperative patients with stage IB-IIB lung adenocarcinoma after surgery and adjuvant chemotherapy：a prospective, cohort, two-center clinical study |
|
|
| Not yet recruiting | N/A | 160 | | Fuzhengquxie prescription ;Without Chinese medicine | Department of Oncology of Shanghai Traditional Chinese Medicine Hospital; Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai Shenkang Hospital Development Center: the second round of three-year action plan major clinical research project | Stage IB-IIB lung adenocarcinoma | | | | |
ChiCTR2000036045: Therapy with FZQXF to prevent the relapse of postoperative patients with early lung adenocarcinoma patients: a randomized, double-blind, placebo-parallel controlled, multicenter clinical trial |
|
|
| Not yet recruiting | N/A | 276 | | Fuzhengquxie Prescription ;Placebo | Department of Oncology of Shanghai Traditional Chinese Medicine Hospital; Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai Shenkang Hospital Development Center: the second round of three-year action plan major clinical research project | Stage IA-IB adenocarcinoma of the lung | | | | |
ChiCTR2400080216: A real-world clinical study investigating the efficacy of Herombopag Olamine in the prevention and treatment of chemotherapy-induced thrombocytopenia in children with solid tumors |
|
|
| Not yet recruiting | N/A | 500 | | For patients having the risk factors of CIT or level 3 and above CIT in the last chemotherapy cycle, the oral administration of hetrombopag was started 24 h after the end of antineoplastic therapy in this cycle. One capsule per day taken without meals. The dose was 2.5 mg/d for patients, and the maximum dose was 7.5mg/d. Meals can be eaten 2 hours after drug administration. Treatment was continued for 7 day to 14 day and a maximum of 4 months. But the drug could not be taken 2 days before the start of the next cycle of chemotherapy and during chemotherapy.; For patients’s platelet count less than 75×109/L after this chemotherapy, the oral administration of hetrombopag was started 24 h after the end of antineoplastic therapy in this cycle. One capsule per day taken without meals. The dose was 2.5 mg/d for patients, and the maximum dose was 7.5mg/d. Meals can be eaten 2 hours after drug administration. Treatment was continued for 7 day to 14 day and a maximum of 4 months. But the drug could not be taken 2 days before the start of the next cycle of chemotherapy and during chemotherapy.; no intervention | West China Second University Hospital, Sichuan University; West China Second University Hospital, Sichuan University, JIANGSU HENGRI MEDICINE CO.LTD | Chemotherapy-induced thrombocytopenia in children with solid tumors | | | | |
ChiCTR2300076968: An exploratory clinical study to explore the effect of hetrombopag on chemotherapy-induced thrombocytopenia in children with solid tumours |
|
|
| Recruiting | N/A | 30 | | Oral administration of hetrombopag was started 24 h after the initiation of antineoplastic therapy in this cycle. The starting dose was 2.5 mg/d for patients aged 1-5 years, 5mg/d for patients aged 6-11 years, and 7.5mg/d for patients aged 12-17 years. The dose was adjusted according to platelet count. However, it was increased by 2.5 mg/d. Blood routine tests were performed at least twice a week during the study, and investigators could increase the frequency of blood routine tests or other tests according to clinical needs. | Shanghai Children's Medical Center Affiliated to Medical College of Shanghai Jiaotong University; Shanghai Children's Medical Center Affiliated to Medical College of Shanghai Jiaotong University, Jiangsu Hengrui Pharmaceutical Co., LTD | Chemotherapy-induced thrombocytopenia in children with solid tumors | | | | |
ChiCTR2400088598: A single-center, randomized, controlled clinical study of Herombopag for the treatment of thrombocytopenia before liver resection |
|
|
| Recruiting | N/A | 96 | | placebo; Herombopag Olamine Tablets | Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, Jiangsu Hengrui Medicine CoLtd | Pre hepatectomy thrombocytopenia | | | | |
ChiCTR2300072983: A clinical study of hetrombopag combined with umbilical cord blood in the treatment of aplastic anemia |
|
|
| Not yet recruiting | N/A | 50 | | IST (ATG + CsA) + hetrombopag + umbilical cord blood ;IST (ATG + CsA) + hetrombopag | Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Self-funded | aplastic anemia | | | | |
ChiCTR2400086043: A single-arm, single-center exploratory clinical study of Herombopag Olamine Tablets in combination with Caffeic acid Tablets for the treatment of cancer therapy-induced thrombocytopenia |
|
|
| Not yet recruiting | N/A | 100 | | Herombopag Olamine Tablets combined with caffeic acid tablets for the treatment of CTIT,Hettropopa ethanolamine tablets: 5mg/ time, once a day, for no more than 14 days; Caffeic acid tablets: 0.3g/ time, three times a day, and continuous medication for no more than 14 days. | Zhongshan Hospital Affiliated to Xiamen University; Zhongshan Hospital Affiliated to Xiamen University, raise independently | the treatment of cancer therapy-induced thrombocytopenia | | | | |
ChiCTR2400082077: Efficacy and safety of retinoic acid in combination with Herombopag in adult patients with Chronic immune thrombocytopenia: A randomized controlled study |
|
|
| Not yet recruiting | N/A | 90 | | Herombopag (2.5mg /50mg orally once daily to achieve and maintain a minimum platelet count of ≥50×109/L for 12 weeks); All-trans retinoic acid (10mg orally twice daily for 12 weeks) + Herombopag (2.5mg /50mg orally once daily to achieve and maintain a minimum platelet | TONGDE HOSPITAL OF ZHEJIANG PROVINCE; TONGDE HOSPITAL OF ZHEJIANG PROVINCE, Tongde Hospital of Zhejiang province | Chronic immune thrombocytopenia | | | | |
ChiCTR2300068232: A Prospective, Single-arm, Multicenter Clinical Study of the Efficacy and Safety of Hetrombopag in the Treatment of Adults with Low-Risk Myelodysplastic Syndrome and Thrombocytopenia |
|
|
| Not yet recruiting | N/A | 43 | | Hetrombopag | The First Affiliated Hospital of Zhejiang University Medical College; The First Affiliated Hospital of Zhejiang University Medical College, Research funding | myelodysplastic syndromes | | | | |
